Eyeworld

Cornea Society News – published quarterly by the Cornea Society 4 Cornea Society symposium to highlight "Management of Chronic and Recurrent Anterior Segment Disorders" T his year during the American Academy of Ophthalmology (AAO) annual meeting, the Cornea Society will cosponsor a symposium on "Management of Chron- ic and Recurrent Anterior Segment Dis- orders." The symposium will take place on Monday, November 13 from 10:15 a.m.–12:15 p.m. in La Nouvelle Orleans Ballroom AB. Anthony Aldave, MD, Los Angeles, one of the chairs of the sympo- sium, discussed some of the topics that will be covered. "Comprehensive ophthalmolo- gists and corneal specialists frequently encounter both chronic and recurrent disorders of the anterior segment," Dr. Aldave said. "While consensus exists regarding the management of many primary anterior segment disorders, the approach to management of recurrent and chronic disorders is more varied, with far less evidence in the ophthal- mic literature to support one approach versus another," he said. "Therefore, in this symposium, the invited faculty will present the audience with a variety of commonly encountered disorders that are refractory to initial, established treatments." Dr. Aldave finds that a key factor in managing challenging clinical disorders is the decision-making process and how a surgeon decides on a particular ther- apeutic strategy. The symposium will present varied approaches to treatment. "By reviewing this decision-making pro- cess with the audience, the faculty will highlight conditions for which a variety of therapeutic approaches are appro- priate, as opposed to those for which only a few approaches or even a single approach is preferred, based on their experience and evidence-based guide- lines," he said. Dr. Aldave intentionally selected conditions that he has found chal- lenging to manage in his practice and asked experts from around the world to provide their approach to diagnosis and management. "Particularly vexing conditions, such as recurrent subepi- thelial infiltrates after epidemic kerato- conjunctivitis, recurrent conjunctival dysplasia, and others, will be presented by experts in the field, who will share their approach to these conditions with the audience," he said. Castroviejo Lecture The Castroviejo Lecture is included in this session every year. This year's lecture will be given by Jonathan Lass, MD, Cleveland, on "Advances with Randomized Clinical Trials in Corneal Transplantation." "Dr. Lass is a most deserving re- cipient of the 2017 Castroviejo Medal, and we are all looking forward to his lecture," Dr. Aldave said. "He will speak on the fact that remarkably few random- ized clinical trials have been performed in the field of cornea, but those that have been performed have had a major impact," Dr. Aldave added. Prime examples that Dr. Lass will describe are the NEI-sponsored Collabo- rative Corneal Transplantation Studies, the Cornea Donor Study, and the recent Cornea Preservation Time Study. With the results of the Cornea Preservation Time Study, for which Dr. Lass was the principal investigator, being presented at this year's Cornea and Eye Banking Fo- rum for the first time, his discussion of the importance and impact of random- ized clinical trials in the field of cornea is particularly timely and relevant, Dr. Aldave said. CN Editors' note: Dr. Aldave has no financial interests related to his comments. Business meeting announcement The Cornea Society business meet- ing will take place on Friday, No- vember 10, during the Cornea and Eye Banking Forum at the Crowne Plaza New Orleans French Quarter, 739 Canal Street at Bourbon, New Orleans. All members are invited to attend. Check the Society website for updates: www.CorneaSociety.org. continued from page 3 included in the program again this year with slightly different topics. Although a comprehensive ophthalmologist wouldn't necessarily be treating tumors, Dr. Jeng noted that it's important to be able to identify them and know what the options are, as many people are un- comfortable with ocular tumors. Case presentations will be included in each section, as they have been for the last several years. The idea, Dr. Jeng said, is to bring in a complex case that ties in the topic of the session with some of the talks in the session to make it real. "It drives home all of the pearls," he said. "We left time for discussion as well," Dr. Jeng said. This allows for audience participation, and audience members will have a chance for an interactive experience by texting in their questions. This allows both for extra audience ques- tions and for speakers to follow up on their topic. The moderators are tasked with trying to make sure all the speakers get a chance to elaborate on their topics, Dr. Jeng said. CN Editors' note: Dr. Jeng has no financial interests related to his comments.

• Blank Page
• Blank Page (1)